Redefining When to Biopsy the Kidney in Patients with SLE # Petri et al. ACR 2025 - Lupus nephritis may be seen in lower proteinuria too (69%) Happy to share similar results from our study-Padiyar S, As C, Gowri M, Mathew J. Lupus. 2024;33(13):1511-1517. @RheumNow

FDA Approves Obinutuzumab for Active Lupus Nephritis The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis. https://t.co/Wr3tG5izCi https://t.co/P8A5PUCIX0

• FDA Approves Obinutuzumab for Active Lupus Nephritis | RheumNow

#ACR25 Beyond blinatumomab, A-319, CD3xCD19 BiTE in 12 patients with #SLE in China reported dose-dependent depth of B-Cell depletion but not efficacy or safety. One withdrew due to AE. No CRS/ICANS. Be interested to see results in larger trials & longer follow-up @RheumNow https://t.co/e5RuZlFI6i

• https://x.com/Yuz6Yusof/status/1982504797036216616/photo/1
• https://x.com/Yuz6Yusof/status/1982504797036216616/photo/1

After propensity matching, this retrospective cohort study showed that #lupus nephritis patients on GLP-1 agonists had ⬇️ CKD progression, mortality & AMI risk vs. LN pts on SGLT2is. Interesting data but what could explain it? Further studies are needed #ACR25 @RheumNow Abs0841 https://t.co/FtsGbMDcCv

• https://x.com/RHEUMarampa/status/1982499968767185041/photo/1

#ACR25 Abstr#645. Dapirolizumab, anti-CD40L-i met primary endpoint, BICLA in Phase 3 RCT non-renal SLE. Key secondary endpoints showed higher rates of & time in LLDAS and remission in DAP vs PBO. Meaningful targets re: damage accrual & better longterm outcomes @RheumNow https://t.co/IxesXhi34R

• https://x.com/Yuz6Yusof/status/1982499943219957924/photo/1
• https://x.com/Yuz6Yusof/status/1982499943219957924/photo/1

#ACR25 Abstr#641 Phase 1/2 CASTLE Basket Trial fully recruited N=24 (10 SLE, 9 SSc, 5 IIM). Short-term data of autologous CD19-CAR T Zorpocabtagene-autoleucel/MB19.1: - 22/24 high degree efficacy - no relapse - no high grade CRS/ICANS *Need larger Phase prior approval @RheumNow https://t.co/sp1nieeCvl

• https://x.com/Yuz6Yusof/status/1982496709860344006/photo/1

Abstract 0806 Compared to belimumab, Anifrolumab associated with: ↑ infection risk b (HR 1.40, 95% CI 1.05–1.88) ↑ herpes zoster (HR 3.94) & COVID-19 (HR 1.66) No diff in mortality or hospital use 📈 3-yr infection: 38.3% vs 21.3% @RheumNow #ACR25

Real world effectiveness of voclosporin for SLE Reduction in UPCR from 2.1 at b/l to 0.9 at 6 months, no improvement in eGFR; as expected based on trials Wonder about market share of BEL vs voclo vs ANI - anyone seen pubs on this? #ACR25 @RheumNow Abstr#0661 https://t.co/l7i7IWhLSe

• https://x.com/EBRheum/status/1982478074810662970/photo/1

Statins and SLE: To add or not to add? 💊 Abstract #0599: In an emulated target trial of patients with SLE, statin users vs non-users had significantly⬇️ risk of all-cause death in both ITT & per-protocol analyses. - No significant differences in MACE or ESKD. @RheumNow #ACR25

SLE & arthritis: Is there a difference? Abstract #0629: - Non-deforming (ND): 73% | Jaccoud’s: 19% | Rhupus: 8% - Vs ND, Rhupus had lower odds of type I IFN signature - Time to deformities: Jaccoud's ~2 yrs vs Rhupus ~5 yrs - RNP+ predictive of Jaccoud’s @RheumNow #ACR25

Managing lupus is complex. How do we ensure quality care? Abstract #0218 convened 8 focus groups: ✅ Support for patient navigators ⚠️ Barriers: low resources, staff turnover 💻 Solution: EHR outreach workflow to flag missed visits & labs @RheumNow #ACR25 https://t.co/BWaIMMEPit

• https://x.com/AkhilSoodMD/status/1982472035658826210/photo/1

Abstract #0607: The age at diagnosis of SLE is rising in US based cohort📈 Those diagnosed ≥30 yrs were: ⬆️ More likely to have oral ulcers, hematologic features, +ANA ⬇️ Less likely to have malar rash or proteinuria @RheumNow #ACR25 https://t.co/pMPVLg1xTZ

• https://x.com/AkhilSoodMD/status/1982472034639814707/photo/1

Abstract 0196: Too many referrals, too few slots? A hybrid RN + MD referral cut wait times for patients with SLE by 26% Median time to appointment 69 days --> 51 days Next steps: streamline high-risk triage, reduce manual chart review @RheumNow #ACR25

Dr. Werth on the #SLE guidelines on tx of cutaneous LE: 🔅All patients should be on hydroxychloroquine unless with CI. ☝️Important! For SLE pts presenting with new-onset rashes, review/ask about medications; consider drug-induced SCLE. #ACR25 @RheumNow https://t.co/ok5jAi7uO0

• https://x.com/RHEUMarampa/status/1982466797971386674/photo/1
• https://x.com/RHEUMarampa/status/1982466797971386674/photo/1

#ACR25 In a rush and wondering which abstract to look out for pertaining to new update on Biologics in #SLE #lupus? Please find my article on conference preview @RheumNow https://t.co/usIXPsj5bm https://t.co/4wmWvDyv83

• SLE Conference Preview: progress in biologics | RheumNow
• https://x.com/Yuz6Yusof/status/1982466449328189855/photo/1